Today: The Hilton Capital Management LLC decides to keep it stake in Celgene Corp. (CELG) to the level of $732,000

The Hilton Capital Management LLC decides to keep it stake in Celgene Corp. (CELG) to the level of $732,000

Hilton Capital Management LLC increased its stake in Celgene Corp. (NASDAQ:CELG) by 1.4% during the third quarter, Holdings Channel reports. The firm owned 7,005 shares of the biopharmaceutical company’s stock after buying an additional 100 shares during the period. Hilton Capital Management LLC’s holdings in Celgene Corp. were worth $732,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Ngam Advisors L.P. raised its stake in shares of Celgene Corp. by 3.6% in the second quarter. Ngam Advisors L.P. now owns 166,196 shares of the biopharmaceutical company’s stock worth $16,392,000 after buying an additional 5,707 shares during the last quarter. Atwood & Palmer Inc. increased its position in Celgene Corp. by 1.7% in the second quarter. Atwood & Palmer Inc. now owns 156,343 shares of the biopharmaceutical company’s stock valued at $15,420,000 after buying an additional 2,543 shares during the period. Fisher Asset Management LLC increased its position in Celgene Corp. by 3.0% in the second quarter. Fisher Asset Management LLC now owns 204,128 shares of the biopharmaceutical company’s stock valued at $21,109,000 after buying an additional 5,968 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its position in Celgene Corp. by 0.8% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,488,765 shares of the biopharmaceutical company’s stock valued at $245,467,000 after buying an additional 20,006 shares during the period. Finally, Putnam FL Investment Management Co. increased its position in Celgene Corp. by 1.4% in the second quarter. Putnam FL Investment Management Co. now owns 117,359 shares of the biopharmaceutical company’s stock valued at $11,575,000 after buying an additional 1,575 shares during the period. Hedge funds and other institutional investors own 77.85% of the company’s stock.

Celgene Corp. (NASDAQ:CELG) traded up 0.17% on Friday, reaching $121.06. 1,792,549 shares of the company were exchanged. The stock has a 50-day moving average price of $108.41 and a 200 day moving average price of $106.51. Celgene Corp. has a 52 week low of $93.05 and a 52 week high of $127.00. The stock has a market capitalization of $93.85 billion, a price-to-earnings ratio of 45.98 and a beta of 1.71.

Celgene Corp. (NASDAQ:CELG) last released its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.48 by $0.10. The company had revenue of $2.98 billion for the quarter, compared to analyst estimates of $2.84 billion. Celgene Corp. had a net margin of 19.71% and a return on equity of 70.48%. The firm’s quarterly revenue was up 27.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.23 EPS. Analysts forecast that Celgene Corp. will post $5.92 earnings per share for the current year.

Several research analysts have commented on CELG shares. Leerink Swann reissued a “market perform” rating and set a $135.00 price objective (up previously from $125.00) on shares of Celgene Corp. in a report on Monday, August 1st. Vetr raised shares of Celgene Corp. from a “sell” rating to a “hold” rating and set a $111.26 price objective for the company in a report on Monday, August 1st. Stifel Nicolaus reissued a “buy” rating and set a $138.00 price objective on shares of Celgene Corp. in a report on Tuesday, August 2nd. Morgan Stanley reissued a “hold” rating and set a $120.00 price objective on shares of Celgene Corp. in a report on Wednesday, August 3rd. Finally, BTIG Research raised shares of Celgene Corp. from a “neutral” rating to a “buy” rating and increased their price objective for the company from $116.14 to $138.00 in a report on Wednesday, August 3rd. Four equities research analysts have rated the stock with a hold rating and twenty-five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $136.30.

In other Celgene Corp. news, Director Michael A. Friedman sold 18,600 shares of the stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $116.10, for a total transaction of $2,159,460.00. Following the sale, the director now directly owns 18,600 shares in the company, valued at approximately $2,159,460. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Corp /De/ Celgene bought 800,150 shares of Celgene Corp. stock in a transaction on Monday, October 24th. The shares were acquired at an average price of $14.00 per share, for a total transaction of $11,202,100.00. The disclosure for this purchase can be found here. Company insiders own 0.97% of the company’s stock.

About Celgene Corp.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Related posts

Leave a Comment